# Form SLICE-W: Worksheet for Designing Individual Field Trials Under SLICE<sup>®</sup> (Emamectin Benzoate) INAD 11-370

## INSTRUCTIONS

- Investigator must fill out Form SLICE-W for each trial conducted under this INAD <u>before</u> actual use of SLICE<sup>®</sup> (emamectin benzoate) medicated feed. The Investigator is responsible for accurate completion of Form SLICE-W.
- 2. Investigator should keep the original on file, and fax a copy to the Study Monitor for review.
- 3. After review, the Study Monitor will fax a copy to the AADAP Office for assignment of the Study Number.
- 4. The AADAP Office will review the worksheet, and then fax the assigned trial Study Number to both the Investigator and Study Monitor, at which time the trial may be initiated.
- 5. Note: Both Investigator and Study Monitor should sign and date Form SLICE-W.

# SITE INFORMATION

Facility			-		
Address			*		
Investigator				 25	
Reporting Ind	ividual (if not Investigator)		*		
Phone		Fax			

# FISH CULTURE AND DRUG TREATMENT INFORMATION

Fish parasite to be treated			1		
Fish species/stock to be treate	d				
Number of fish per rearing un	it (i.e., tank, racewa	y, or pond)			
Number of rearing units to be treated		Number of untreated (i.e., control) rearing units			
Average number of fish per pound		Estimated total weight of treated fish (lbs)	(s)		
Intended SLICE® (emamectin	benzoate) dosage	50 ug per kg per day			
Feed rate (% body weight to b	e fed per day)				
Planned duration of treatment	(days)	7 Te			
Estimated amount of medicat	ed feed needed for	proposed treatment (lbs or kg)			
Anticipated date treatme	ent will be initiated	<u>а</u>			

# Worksheet for Designing Individual Field Trials (cont.)

Page 2 of 2

**STUDY DESIGN:** Describe in detail the purpose of the clinical trial. Study design must be carefully focused and lend itself to rigorous evaluation. If more space is required to describe study details, title additional page(s) "Study Design" and attach them to this Worksheet.

Investigator should initial here to indicate that all personnel handling SLICE® (emamectin benzoate) medicated feed have read the Material Safety Data Sheet for SLICE® (emamectin benzoate) premix and have been provided personal protective equipment, in good working condition, as described in the Study Protocol.  Date    Investigator:						
Investigator should initial here to indicate awareness that fish disposition must be in compliance with the FDA-mandated withdrawal time of 60 days as described in the Study Protocol.  USE AND DISPOSITION OF EMAMECTIN BENZOATE (SLICE®)  MEDICATED FEED (Environmental Safety Considerations):  Investigator should initial here to indicate awareness that SLICE® (emamectin benzoate) medic feed usage and disposition must be in compliance with requirements described in the Study Protocol.  WORKER SAFETY CONSIDERATIONS:  Investigator should initial here to indicate that all personnel handling SLICE® (emamectin benzoate) medicated feed have read the Material Safety Data Sheet for SLICE® (emamectin benzoate) premix and have been provided personal protective equipment, in good working condition, as described in the Study Protocol.  Date  Investigator:  Investigator:	Study designed by				×.	
compliance with the FDA-mandated withdrawal time of 60 days as described in the Study Protocol.  USE AND DISPOSITION OF EMAMECTIN BENZOATE (SLICE®)  MEDICATED FEED (Environmental Safety Considerations):  Investigator should initial here to indicate awareness that SLICE® (emamectin benzoate) medic feed usage and disposition must be in compliance with requirements described in the Study Protocol.  WORKER SAFETY CONSIDERATIONS:  Investigator should initial here to indicate that all personnel handling SLICE® (emamectin benzoate) medicated feed have read the Material Safety Data Sheet for SLICE® (emamectin benzoate) premix and have been provided personal protective equipment, in good working condition, as described in the Study Protocol.  Date    Investigator:	DISPOSITION	N OF TREATED FI	SH (Human Foo	od Safety Consideration	ns):	
Investigator should initial here to indicate awareness that SLICE® (emamectin benzoate) medic feed usage and disposition must be in compliance with requirements described in the Study Protocol.  WORKER SAFETY CONSIDERATIONS:  Investigator should initial here to indicate that all personnel handling SLICE® (emamectin benzoate) medicated feed have read the Material Safety Data Sheet for SLICE® (emamectin benzoate) premix and have been provided personal protective equipment, in good working condition, as described in the Study Protocol.  Date  Prepared:  Investigator:	complian	ce with the FDA-mandate	ndicate awareness t ed withdrawal time	hat fish disposition must be of 60 days as described in t	e in the Study	
Investigator should initial here to indicate awareness that SLICE® (emamectin benzoate) medic feed usage and disposition must be in compliance with requirements described in the Study Protocol.  WORKER SAFETY CONSIDERATIONS:  Investigator should initial here to indicate that all personnel handling SLICE® (emamectin benzoate) medicated feed have read the Material Safety Data Sheet for SLICE® (emamectin benzoate) premix and have been provided personal protective equipment, in good working condition, as described in the Study Protocol.  Date    Investigator:   Investigat	USE AND DIS	POSITION OF EM	AMECTIN BE	NZOATE (SLICE®)	2	
feed usage and disposition must be in compliance with requirements described in the Study Protocol.  WORKER SAFETY CONSIDERATIONS:  Investigator should initial here to indicate that all personnel handling SLICE® (emamectin benzoate) medicated feed have read the Material Safety Data Sheet for SLICE® (emamectin benzoate) premix and have been provided personal protective equipment, in good working condition, as described in the Study Protocol.  Date  Prepared:  Investigator:					4	
Investigator should initial here to indicate that all personnel handling SLICE® (emamectin benzoate) medicated feed have read the Material Safety Data Sheet for SLICE® (emamectin benzoate) premix and have been provided personal protective equipment, in good working condition, as described in the Study Protocol.  Date    Investigator:	feed usage					1
benzoate) medicated feed have read the Material Safety Data Sheet for SLICE® (emamectin benzoate) premix and have been provided personal protective equipment, in good working condition, as described in the Study Protocol.  Date    Investigator:	WORKER SA	FETY CONSIDERA	ATIONS:	8 #		
Prepared:	benzoate benzoate	) medicated feed have re ) premix and have been p	ad the Material Safe rovided personal pr	ety Data Sheet for SLICE®	(emamectin	
Prepared:		ži.	8			
		· · · · · · · · · · · · · · · · · · ·	Investigator:		A	
Date Reviewed: Study Monitor:	Date Reviewed:		Study Monitor:			

# FORM SLICE-1. Report on Receipt of Drug - Guide for Reporting Investigational New Animal Drug Shipments for Poikilothermic Food Animals

## INSTRUCTIONS

- 1. Investigator must fill out Form SLICE-1 <u>immediately</u> upon receipt of SLICE® (emamectin benzoate) premix or SLICE® (emamectin benzoate) medicated feed.
- 2. Investigator should keep the original on file, and send one copy to the Study Monitor for review.
- 3. Within 10 days of receipt, the Study Monitor should send a copy to the AADAP Office.
- 4. Note: Both Investigator and Study Monitor should sign and date Form SLICE-1.

The sponsor, <u>U.S. Fish and Wildlife Service</u>, submits a notice of claimed investigational exemption for the shipment or delivery of a new animal drug under the provisions of Section 512 of the Federal Food, Drug, and Cosmetics Act. The following information is submitted in triplicate:

Name of Drug	SLICE® (Emamectin benzoate)	INAD Number	11-370
Proposed Use of Drug	Treatmen	nt of external parasites that occur freshwater fish species	in a variety of
Date of CVM Authorization Letter		To be Determined	
Date of Drug Receipt		Amount of Drug Received	*
Drug Lot Number		Trial Number	
Name of Investigator		¥ 4	-
Address of Investigator			
Location of Trial		* 3	
Pivotal Study	Yes	Non-pivotal Study	
Approximate Number of Treated Animals		Approximate Number of Control Animals	
Number of Animals Used Previously			
Study Protocol Number	ing Spanish Section 1995	11-370	
Approximate dates of trial (start/end)		40	
Species, Size, and Type of Animals		2 778	
Maximum daily dose and duration	50 ug e	mamectin benzoate / kg fish / day	for 7 days
Methods(s) of Administration		Medicated-feed	
Withdrawal Period		60 days - all species	
To be filled out by the AADAP Office	Ŷ	= 0.11 - 1.00 NV	
Date Prepared:	Inve	estigator:	
Date Reviewed:	Study	Monitor:	
Date Reviewed:		Sponsor:	

# Revised: 4/10

# Chemical Use Log for Clinical Field Trials Using SLICE $^{ ext{@}}$ (emamectin benzoate) Medicated Feed Under INAD #11-370 - SLICE® Premix Form SLICE-2a.

1. Initiate Form 2a immediately upon receipt of SLICE® (emamectin benzoate) premix.
2. Each lot number of SLICE® (emamectin benzoate) premix may be used for multiple t 3. A signed copy of Form 2a should be sent to the Study Monitor at the end of the Study 4. Original Form 2a should be sent to the Study Monitor at the end of the Study 4. Instructions:

Each lot number of SLICE® (emamectin benzoate) premix may be used for multiple treatment regimes.

A signed copy of Form 2a should be sent to the Study Monitor at the end of the Study Year.

	Inventoried by (initials)									
dual:	SLICE® Premix On-hand (g)					9		.1 1		
Individual:	SLICE® Premix Disposal² (g)									
	SLICE® Premix Shipped¹ (g)	8			S. 3884					
	SLICE® Premix Used for Teatment (g)		6							
	Study Number									
Facility:	Date Used	15	2							
	Amount Received (g)						· 图 · 图 · 图 · 图 · 图 · 图 · 图 · 图 · 图 · 图	125		<b>阿里斯斯斯</b>
(lbs):	Date Received							X 2.5		· · · · · · · · · · · · · · · · · · ·
Quantity on hand From Previous Page (lbs): _	SLICE® Premix Lot Number	(4								は 一個 の は の の の の の の の の の の の の の の の の の

	4
	Signature and Da
Investigator:	

Study Monitor:

Signature and Date

<sup>&</sup>lt;sup>1</sup> Unused SLICE® Premix that is shipped to another facility participating in SLICE® INAD #11-370 (Note: SLICE® Premix can only be shipped to another facility with prior authorization by the AADAP Office).

<sup>&</sup>lt;sup>2</sup> Unused SLICE® Premix that is disposed of by burial or in a landfill.

# Revised: 4/10

# Chemical Use Log for Clinical Field Trials Using SLICE® (emamectin benzoate) Medicated Feed Under INAD #11-370 - SLICE® Medicated Feed Form SLICE-2b.

Initiate Form 2b immediately upon receipt of SLICE® (emamectin benzoate) medicated feed.

Each lot number of SLICE® (emamectin benzoate) medicated feed should be used for a single treatment regime.

A signed copy of Form 2b should be sent to the Study Monitor at the end of the study, or at the end of the Study Year.

Original Form 2b should be archived at the investigating facility. Instructions:

Quantity on Hand From Previous Page (lbs):	e (lbs):	Î	Facility:				Reporting Individual:	ng ial:	J
SLICE® Medicataed Feed Lot Number	Date Received	Amount Received (lbs)	Dates Used	Study Number	SLICE® Medicataed Feed Used for Teatment (lbs)	SLICE* Medicataed Feed Shipped¹ (lbs)	SLICE® Medicataed Feed Disposal² (lbs)	SLICE® Medicataed Feed On-hand (lbs)	inventoried by (initials)
			×	2:					
		4.00 PER 1							
					(2)				
	Transfer A					46			
									*
			ĸ						
								3	
			· S						
									×

Investigator:		Study M
	Signature and Date	

Signature and Date Monitor:

<sup>1</sup> Unused SLICE® medicataed feed that is shipped to another facility participating in SLICE® INAD #11-370 (Note: SLICE® medicataed feed can only be shipped to another facility with prior authorization by the AADAP Office).

<sup>2</sup> Unused SLICE® medicataed feed that is disposed of by burial or in a landfill.

# Form SLICE-3: Results Report Form for Clinical Field Trials Using SLICE® (emamectin benzoate) Medicated Feed Under INAD 11-370

## **INSTRUCTIONS**

- Investigator must fill out Form SLICE-3 no later than 10 days after completion of treatment. Study Number must be recorded on all pages of Form SLICE-3. Attach lab reports and other information.
- 2. If SLICE® (emamectin benzoate) was not used under the assigned Study Number, fill out only the Site Information portion on this page, and skip to the end of page 4 and fill out only the "Negative Report" section.
- 3. Investigator should keep the original on file, and send a copy to the Study Monitor. Within 10 days of receipt, the Study Monitor should send a copy to the AADAP Office for inclusion in the permanent file.
- 4. Note: Both Investigator and Study Monitor should sign and date Form SLICE-3.

# SITE INFORMATION

Facility	*
Reporting Individual	

# FISH CULTURE AND DRUG TREATMENT INFORMATION

SLICE® (emamectin benzoate) lot number		Medicated feed manufacture/preparation date	
Treatment dosage	50 ug/kg bw/day	Treatment duration	7 days
Fish species treated		Fish parasite treated	
Number of rearing units treated		Number of fish per treated rearing unit	•
ID of all treated rearing units	(e.g. Tank 5, Pond 6B)		
Total nu	mber of fish treated	74 76 21	
Number of control units		Number of fish per control unit	
Number of fish per pound		Average fish length (in)	
Preparation of medicated feed (i.e. top-coated at your facility or prepared by feed manufacturer)			
Feed type (manufacturer, moist <u>vs</u> dry, particle size)			;•
Feed rate (% BW fed per day	·)		
Date treatment initiated		Date treatment completed	

# **Daily Mortality Record**

## INSTRUCTIONS

- 1. Investigator must fill out the Daily Mortality Record as completely as possible.
- 2. Prior to initiation of the trial, fill out Rearing Unit ID, whether a rearing unit is <u>Treated or Control</u>, and the number of fish in each rearing unit.
- 3. Water temperature and individual tank mortality should be recorded on a daily basis.
- 4. Use additional copies of this form if more than 6 rearing units are involved in the trial.

FACIL	ITY									
	Re	aring U	nit ID							8
	Trea	ated or <u>C</u>	<u>C</u> ontrol							
	Nu	mber o	f Fish		9					
	Day	Date	Water Temp (F°)	Mortality	Mortality	Mortality	Mortality	Mortality	Mortality	Daily Observer Initials
В	5									15
Peri	4			-72%						
Treatment Period	3									
	2									
	1								3	
	1									
	2									
	3									
	4									E
	5						a.		2	
	6									
	<b>7</b>									131333
	1									
Post-treatment Period	2									
	3									
	4						-	X		
	5									20
	6									
-trea	7									
Post	8									
	9							3		
)	10									

# Daily Mortality Record (Supplemental Post-treatment Period Data)

# **INSTRUCTIONS**

- 1. Investigator should fill out the Daily Mortality Record (Supplemental Post-treatment Period Data) only if data is collected for more than 10 days post-treatment.
- 2. Use additional copies of this form if more than 6 rearing units are involved in the trial.

FACI	LITY									
	Re	aring U	nit ID							
	Trea	ated or <u>C</u>	<u>C</u> ontrol							
	Nu	mber o	f Fish							
	Day	Date	Water Temp (F°)	Mortality	Mortality	Mortality	Mortality	Mortality	Mortality	Daily Observer Initials
	11									
	12									5
	13						-			
Post-treatment	14									
	15	¥(			8:			-	9	
	16					9	-			
	17		· A							
	18									•
	19									
	20									7
	21						7			
	22									
	23	· ·								
	24						+			
	25									
	26									
	27				130					
	28									

pH G GO ( M)	
TY 1 G GO ( T)	
Hardness - CaCO <sub>3</sub> (mg/L)	
treatment successful? If treatment of avior, including feeding behavior. Vereatment results? Were there	Vere there any
8 9	
21 a.	-
2	
*	
W	
reatment post-treatment	
	E
city including a description of unusu	al fish behavior.
, ,	X)
*	
*	
*	
tigator should initial here to indicate lished withdrawal period	compliance with
-	compliance with
-	compliance with
	avior, including feeding behavior. Veracted treatment results? Were there are the remarks are

STUDY NUMBER

Form SLICE-3 Results Report Form

Page 4 of 5

Revised: 4/10

STUDY NUM	Page 5 of 5
	N A
(mC)	
DISPOSITION	OF SLICE® (EMAMECTIN BENZOATE) MEDICATED FEED
	Use and disposition of all SLICE® (emamectin benzoate) medicated feed followed Study Protocol guidelines and has been clearly identified on Form SLICE-2b (Investigator should initial)
4	NEGATIVE REPORT: SLICE® (emamectin benzoate) medicated feed was not used at thi facility under this Study Number during the reporting period (Investigator should initial for negative reports as soon as the Study Number is known to be no longer needed or valid
Date Prepared:	Investigator:
Date Reviewed:	Study Monitor:

STUDY NUMBER:	
---------------	--

Form SLICE-3s: Supplemental Information Documenting Level of Parasite Infestation Pre-Treatment and Post-Treatment

### INSTRUCTIONS

- 1. Investigator should fill-out one copy of Form SLICE-3s for each rearing unit treated.
- 2. Be sure to include STUDY NUMBER in upper left-hand corner of this form.
- 3. Data on Pre-treatment level of infestation should be collected within 5 days prior to the initiation of treatment.
- 4. Data on Post-treatment level of infestation should be collected at least once.
- 5. Note: Each sampling (i.e., pre- and post-treatment) should include data from a minimum of 10 fish, and completed Form SLICE-3s's should be appended to Form SLICE-3.

Rearing	<b>Unit ID:</b>	

1	Pre-treatm	ent
Date	Fish Number	Number of Parasites
	1	
	2	
	3	
alm fis ()	4	
	5	
	6	
	7	
	8	
	9	
	10	
	11	
	12	
	13	
Line a	14	
	15	-
	16	
	17	
	18	
	19	
	20	
	21	1
	22	
100	23	
	24	
	25	
	26	
	27	
	28	
	29	
	30	

Post-treatment <sup>1</sup>			
Date	Days Post- treatment	Fish Number	Number of Parasites
		1	
		2	
		3	
· ·		4	
		5	
(1) For all (1)		6	
		7	
		8	
		9	
		10	
		11	
		12	
		13	
		14	
		15	
		16	
		17	10.
		18	
		19	
		20	
		21	
		22	
		23	
		24	
		25	
		26	
		27	
		28	
		29	
		30	

<sup>&</sup>lt;sup>1</sup> Additional copies of table for post-treatment infestation level are available on page 2 of this form

# Additional Documentation of Level of Parasite Infestation Post-Treatment

1	Note:	If data on post-treatment level of parasite infestation is only collected once,
		please simply write "N/A" in the box

Rearing	<b>Unit ID:</b>	

Post-treatment			
Date	Days Post- treatment	Fish Number	Number of Parasites
		1	111-
		2	
		3	
		4	
		5	×
	Part and Ser	6	
M.		7	
		8	
		9	
Alle S		10	
17/10 2017		11	
		12	
To be a second		13	
		14	
		15	
		16	5
		17	
		18	14
5		19	
		20	
		21	
		22	
		23	
		24	
		25	
		26	
		27	
AND THE R		28	
(16) (E. 16) (E. 16) (E. 16)		29	
		30	

Post-treatment			
Date	Days Post- treatment	Fish Number	Number of Parasites
		1	
		2	
		3	
		4	
		5	
		6	
		7	
		8	
	199	9	
		10	
		11	
		12	
		13	
		14	
		15	
		16	
	1 P/2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	17	
		18	
		19	
		20	
		21	
		22	
		23	
		24	
		25	
		26	
		27	
		28	
		29	
	The State of	30	